Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Active Not Recruiting
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/01/2025
Locations: Physician Research Collaboration, LLC, Lincoln, Nebraska
Conditions: Psoriatic Arthritis, Obesity